RxDoctor Payments Data

Lawrence Bish, MD

Cardiovascular Disease · Doylestown, PANPI 1871883603

Payments from drug & device makers

$3,642in general payments, 2019–2025

Across 220 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$835
  • Pfizer$386
  • Amgen$369
  • Merck$340
  • E.r. Squibb & Sons, L.L.C.$244
  • Johnson & Johnson$228
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,631100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,642 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$251,456
Medicare patients
1,884
Services billed
4,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban584$735,669
XareltoRivaroxaban76$105,844
EntrestoSacubitril/Valsartan66$91,839
Repatha SureclickEvolocumab62$61,693
FarxigaDapagliflozin Propanediol43$42,603
Praluent PenAlirocumab23$26,442
JardianceEmpagliflozin14$22,421
VascepaIcosapent Ethyl27$20,937
Rosuvastatin Calcium879$15,974
NexlizetBempedoic Acid/Ezetimibe18$10,007
Icosapent Ethyl32$9,363
Metoprolol Succinate557$9,160
Ezetimibe362$7,705
BrilintaTicagrelor13$7,207
Atorvastatin Calcium360$6,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$386$735,669584 claims
Johnson & JohnsonXarelto$228$105,84476 claims
NovartisEntresto$835$91,83966 claims
AstraZenecaFarxiga, Brilinta$163$49,81056 claims
Boehringer IngelheimJardiance$182$22,42114 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$78$15,18431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →